SARS is not a model for coronavirus

Chris Kushlis, Credit Analyst
Tomasz Wieladek, T. Rowe Price International Economist

Key insights

  • The potential impact of the COVID‑19 virus on the Chinese economy has been compared with that of the SARS virus in 2003.
  • However, there were external factors weighing on the Chinese economy in 2003 that do not exist today.
  • We believe our approach, based on calculating the impact of lost working days on production, provides a more accurate assessment of the economic impact of COVID‑19.
Commentators seeking to understand the long‑term implications of COVID‑19 (a coronavirus) are frequently comparing it with the 2002–2003 severe acute respiratory syndrome (SARS) outbreak, which had a severe impact on both the Chinese and the global economies. But the 2003 SARS outbreak coincided with slowing global gross domestic product (GDP) growth, the Iraq War, and higher oil prices. So is SARS really a good case study for understanding the likely economic effects of COVID‑19? And if it is not, what other evidence can we turn to?

Chinese GDP growth during the SARS outbreak

(Fig. 1) The impact of the virus appears at first glance to be severe.

Graph 1

Analysis as of February 14, 2020.
Source: National Bureau of Statistics.

The SARS outbreak caused 8,098 cases and 774 deaths in 17 countries. Although the first cases appeared as early as November 2002, it was not until April 2003 that the World Health Organization issued a global health alert. Shortly afterwards, the Chinese authorities announced that all primary and secondary schools would be closed for two weeks and closed down other public venues, such as theatres and discos.

There are significant differences between the situation today and that of China in 2003.

– Chris Kushlis, Sovereign Analyst

Macroeconomic developments in 2003

(Fig. 2) Growth declined, and oil production fell.

Graph 2

Analysis as of February 14, 2020.
Source: Organisation for Economic Co‑operation and Development.

It was also in April 2003 that the first quarantine measures were introduced. As Figure 1 shows, this coincided with a significant reduction in Chinese Q2 2003 GDP growth in which the quarter‑on‑quarter growth rate fell by 2.1% (from 2.9% in Q1 2003 to 0.8% in Q2 2003). This decline was driven by a reduction in services and manufacturing growth, which was likely partly caused by containment measures taken by the Chinese government. Many observers, therefore, argue that the SARS episode is a good case study from which to extrapolate the effects of COVID‑19.

However, there are significant differences between the situation today and that of China in 2003. Then, China composed only 5% of the world economy and was just in the process of becoming central to global supply chains on the back of its World Trade Organization accession in 2001. Rather than being a driver of the world economy, China was more a recipient of fluctuations and shocks from elsewhere.

Moreover, there were two important global economic developments occurring at the same time (Figure 2): First, in early 2003, growth in G7 economies (75% of global GDP at the time) was slowing; and second, in anticipation of the US invasion of Iraq, which reduced global oil production by around 2%. The Q2 2003 Chinese slowdown is often wholly attributable to SARS, but is it possible that these two macro factors may also have played a part?

We used a simple linear regression analysis to determine the extent to which industrialized country growth and real oil price growth rates impacted Chinese GDP growth from Q1 2001 to Q4 2007. The residual from this regression shows the impact on growth from idiosyncratic factors over the period. Figure 3 shows the results from this exercise. The grey line shows Chinese growth predicted by the global factors in the regression model and indicates that these would have led to a moderation of growth in China without the outbreak of SARS.

The residual weakness in growth, which can be attributed to China‑specific factors in that quarter, is 1%—much lower than the 2.1% effect that can be calculated by looking at quarterly growth rates alone.

The coincidental global slowdown and rise in real oil prices mean that the effect of SARS was likely greatly exaggerated in Chinese GDP data.

– Tomasz Wieladek, International Economist

Overall, the coincidental global slowdown and rise in real oil prices mean that the effect of SARS was likely greatly exaggerated in Chinese GDP data. In our view, SARS is, therefore, not a good case study for understanding the potential economic consequences of COVID‑19 on Chinese real GDP growth.

The impact on Chinese GDP of domestic and external factors

Graph 3

(Fig. 3) SARS had less of an effect than first thought.

Analysis as of February 14, 2020.
Source: National Bureau of Statistics, Organization for Economic Co‑operation and Development. Dataanalysis by T. Rowe Price. Results predicted from the regression model (light blue and gray lines) areestimates and do not represent actual results.

If SARS is not a good case study to assess the economic impact of COVID‑19, what should investors look at instead? We believe that the most useful approach is to quantify the effect of lost working days on overall production. We estimate that the current measures imposed by the Chinese government through early February have led to eight lost working days for the country as whole. A reduction in one working day in Q1 leads to roughly a 0.4% loss in output, meaning that the eight lost working days so far translate into a quarterly growth reduction of 3.2%. This number is 50% larger than 2.1% growth impact measured during the SARS outbreak, and three times as large as the estimated 1% impact adjusted for external factors. Although this number could rise further, it is significantly smaller than extrapolating the economic impact based on virus cases in China, which, with 78,000 cases to date, is 15 times larger than the 5,237 cases that China experienced during SARS.

We believe that by looking at the sensitivity of growth to each working day lost (0.4% of GDP), we can get a much better sense of the economic impact of COVID‑19 than can be obtained from arbitrarily scaling up the consequences of SARS. The same method can be applied to the impact of COVID‑19 on growth in other countries that have been badly hit by the virus, including Italy.

We will continue to track high‑frequency indicators around travel patterns, pollution, and coal consumption at power plants. This will help us to more accurately gauge how many effective working days have been lost in real time and, therefore, what the economic impact is likely to be—and to do so significantly ahead of the publication of longer‑term hard data.

What we’re watching next

We will be closely monitoring developments in COVID‑19 over the coming weeks and months and modifying our assessment of its likely impact on the Chinese and global economies as new data come in. In particular, we will look closely at working days lost in order to gain a better understanding of the potential effect the virus may have on Chinese GDP.

To earn 20 mins of structured CPD, read this article and complete the short assessment on Adviser Home.

Sign up for US Equity insights from T. Rowe Price

Share this article:

Share on linkedin
Share on email
T.Rowe Price 2020 Election Blog
US Flag

Election 2020

Our US Political analyst reports from Washington on the campaign trail, see our insights into the impact of the election on your investments.

Important Information

For professional clients only. Not for further distribution.

This material is being furnished for general informational purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, and prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources’ accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date noted on the material and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request.

It is not intended for distribution to retail investors in any jurisdiction.


You might be interested in…

See our comprehensive range of US equity funds

Thank you for registering for US equities updates. The latest insights will be sent straight to your inbox, in the meantime access our latest thinking:

Important Legal Information

This site is intended for financial intermediaries in the United Kingdom. I have read the terms detailed below and confirm that I am a financial intermediary and that I wish to proceed. By accessing this website, you consent to T. Rowe Price collecting information by way of cookies.

Information contained in the T. Rowe Price website is not intended for investors in any jurisdiction in which distribution or purchase is not authorised, including the jurisdiction of the reader of this information, where applicable. For example, the information herein is not for distribution to and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States of America to or for the benefit of United States persons.

Information obtained from this site is intended specifically for the individuals who have agreed to these Terms and Conditions and may not be redistributed without prior consent from the T. Rowe Price Legal department.

The information is designed for professional investors, including financial intermediaries or members of the media, and is published for informational purposes only. In particular, the information is directed at only informing persons falling within one or more of the following categories:

(a) A government;
(b) A bank or insurance company;
(c) A pension fund or charity;
(d) Persons whose ordinary activities involve them, as principal or as agent, in acquiring, holding, managing or disposing of investments for the purposes of a business carried on by them or whom it is reasonable to expect will, acquire, manage or dispose of investments for the purpose of such a business;
(e) Persons whose ordinary business involves the giving of advice, which may lead to another person acquiring or disposing of an investment or refraining from so doing;
(f) Representatives of the media for corporate and background information about T. Rowe Price.

Persons who do not fall into one of the above categories should not act upon the information contained herein.

Certain persons may have access to information regarding the T. Rowe Price Funds SICAV, an investment company incorporated as “Société d’Investissement à Capital Variable” (‘SICAV’) under the laws of Luxembourg and the T. Rowe Price Funds OEIC, an open-ended investment company (‘OEIC’) incorporated in England and Wales. The sub-funds referred to on the site are only offered by the current prospectus. The prospectus contains more complete information about the sub-funds, including investment objectives, charges and expenses. However, the prospectus and other information relating to the sub-funds will not be intentionally distributed to persons in any country where such distribution would be contrary to local law or regulation.

Past performance is not a guide to future performance. The value of securities and any income generated from them might decrease as well as increase. Changes in rates of exchange may also have an adverse effect on the value, price or income of securities. Investors should also be aware of the additional risks associated with investments in emerging markets, high yield securities and smaller companies.

This information herein does not constitute investment advice and the products described may not be available to or suitable for all investors. You should consider, if appropriate, obtaining independent professional advice before making an investment decision.

Unless otherwise noted, the content appearing in this Section of the T. Rowe Price website has been issued by T. Rowe Price International Ltd, 60 Queen Victoria Street, London EC4N 4TZ, which is authorised and regulated by the U.K. Financial Conduct Authority with the reference number 194667.